News
NBY
0.0821
+6.62%
0.0051
Weekly Report: what happened at NBY last week (0415-0419)?
Weekly Report · 4d ago
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
NovaBay Pharmaceuticals, Inc. Announces a new and enhanced marketing program that includes text message communications and targeted email programs to drive online sales of Avenova products. The company is developing and commercializing high-quality eyecare and wound care products. NovaBay’s leading product is the Avenova Antimicrobial Lid & Lash Solution.
Barchart · 4d ago
NovaBay Pharmaceuticals receives NYSE notice for compliance
NovaBay Pharmaceuticals, Inc. Receives NYSE notice for compliance. The stock price dropped 2.8% on Friday during after hours of trade. The company must submit a plan by May 18, 2024 to continue listing on the NYSE American. The notice has no immediate effect on the company's stock.
Seeking Alpha · 4d ago
NOVABAY PHARMACEUTICALS RECEIVES A NYSE AMERICAN NOTICE REGARDING STOCKHOLDER EQUITY
Reuters · 6d ago
NOVABAY PHARMACEUTICALS: ON APRIL 18, GOT NOTICE FROM NYSE AMERICAN STATING CO IS BELOW COMPLIANCE WITH NYSE AMERICAN CONTINUED LISTING STANDARDS
Reuters · 6d ago
NovaBay Pharmaceuticals show 13% rise in eyecare and wound care segment - prelim report
Seeking Alpha · 04/17 11:23
NOVABAY PHARMACEUTICALS REPORTS PRELIMINARY EYECARE AND WOUND CARE REVENUE INCREASED 13% FOR THE FIRST QUARTER OF 2024 ON LOWER SALES AND MARKETING EXPENSES
Reuters · 04/17 10:59
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
NovaBay Pharmaceuticals, Inc. Reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million. The increase is attributed primarily to social media marketing programs aimed at consumer sales of the Company’s lead product, Avenova Antimicrobial Lid & Lash Solution.
Barchart · 04/17 05:59
Weekly Report: what happened at NBY last week (0408-0412)?
Weekly Report · 04/15 12:18
Buy Rating Maintained for NovaBay Pharma Amid Strategic Refocus and Resilient Revenue Performance
TipRanks · 04/15 09:16
NOVABAY PHARMACEUTICALS INC <NBY.A>: ASCENDIANT CAPITAL MARKETS CUTS TARGET PRICE TO $2 FROM $3.5
Reuters · 04/15 03:07
Weekly Report: what happened at NBY last week (0401-0405)?
Weekly Report · 04/08 12:23
Weekly Report: what happened at NBY last week (0325-0329)?
Weekly Report · 04/01 12:19
NBY Stock Earnings: NovaBay Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023
NovaBay Pharmaceuticals reported earnings per share of -21 cents. The company reported revenue of $3.73 million. This was 9.62% better than the analyst estimate for revenue of -20 million. The stock was down 2.7% after the market closed.
Investorplace · 03/27 01:53
NovaBay Pharmaceuticals: Q4 Earnings Insights
NovaBay Pharmaceuticals reported its Q4 earnings of $-0.21 on March 26. The company beat estimates by 30.0%. The company's revenue was up $84 thousand from the same period last year. NovaBay pharmaceuticals is expected to announce its earnings Tuesday.
Benzinga · 03/26 21:20
NovaBay Pharmaceuticals Q4 EPS $(0.21) Beats $(0.30) Estimate, Sales $3.73M Beat $3.40M Estimate
NovaBay Pharmaceuticals reports quarterly losses of $0.21 per share. The company reported quarterly sales of $3.73 million which beat the analyst consensus estimate by 9.62%. The company also reported a 30 percent increase in sales from the same period last year.
Benzinga · 03/26 21:18
*NovaBay 4Q Loss $4.11M >NBY
Dow Jones · 03/26 20:05
Press Release: NovaBay Pharmaceuticals Reports -2-
(or the execution on capital raise opportunities) not being sufficient to meet the Company's cash needs. Other risks relating to NovaBay's business are detailed in the company's latest Form 10-K/Q filings with the Securities and Exchange Commission. The forward-looking statements in this release speak only as of the date of this release.
Dow Jones · 03/26 20:05
*NovaBay 4Q Sales $3.73M >NBY
Dow Jones · 03/26 20:05
Earnings Scheduled For March 26, 2024
Bluebird bio is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. AIM ImmunoTech is estimated to report earnings for its fourth quarter. Elbit Systems is projected to report. Quarterly earnings at $1.38 per share.
Benzinga · 03/26 08:47
More
Webull provides a variety of real-time NBY stock news. You can receive the latest news about Novabay Pharma through multiple platforms. This information may help you make smarter investment decisions.
About NBY
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and wound care products. Its product, Avenova Antimicrobial Lid and Lash Solution, has antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. It offers a portfolio of products for each step of the standard at home treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. It also manufactures and sells its proprietary form of hypochlorous acid for the wound care market with its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers and other injuries.